Rocket Pharmaceuticals raises ~$188.9M in public offering of common stock and pre-funded warrants

ROCKET PHARMACEUTICALS, INC.

Offered 7,812,500 shares at $16.00/share and pre-funded warrants for 3,126,955 shares at $15.99 each.
Underwriters exercised full 30-day option to purchase an additional 1,640,918 shares.
Net proceeds of ~$188.9M to fund gene therapy pipeline including RP-A501 Phase 2 trial.
90-day lock-up agreements for executive officers, directors, and certain shareholders.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

ROCKET PHARMACEUTICALS, INC. entered into Underwriting Agreement with J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC, Leerink Partners LLC and Cowen and Company, LLC (effective 2023-09-12).

Action: entry
Agreement: underwriting
Counterparty: J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC, Leerink Partners LLC and Cowen and Company, LLC
Effective: 2023-09-12

Exact text from the filing

On September 12, 2023, Rocket Pharmaceuticals, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC, Leerink Partners LLC and Cowen and Company, LLC, as representatives of the several underwriters named in Schedule A thereto (collectively, the “Underwriters”), pursuant to which the Company agreed to issue and sell up to (i) 7,812,500 shares of common stock (the “Shares”), and (ii) pre-funded warrants (the “Pre-Funded Warrants”) to purchase 3,126,955 shares of common stock (the “Offering”).

View on SEC.gov

Browse all material agreements →

ROCKET PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001140361-23-044141

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.